case_images: PMC11228259_01
case_images: Metabolic monitoring before and after 10 months of SGLT2 inhibitor therapy. TAR, time above range; TIR, time in range; TBR, time below range.
case_images: fgene-15-1414451-g001.jpg
case_images: PMC11228259_01_fgene-15-1414451-g001.jpg
case_images: F1
case_images: Thereafter, 10 months after the initiation of therapy, the time in range (TIR) increased from 47% (with metformin monotherapy) to 63% with empagliflozin 2.5 mg (first month of therapy), reaching 74% with empagliflozin 5 mg. (Figure 1).
case_images: Clinical course of the patient before and after SGLT2i treatment. HbA1c, hemoglobin glycated (%). SGLT2i, sodium-glucose cotransporter 2 inhibitor.   start of SGLT2i treatment.
case_images: fgene-15-1414451-g002.jpg
case_images: PMC11228259_01_fgene-15-1414451-g002.jpg
case_images: F2
case_images: Glycated hemoglobin decreased from 8.5% to 7.1% during the same period, indicating a noteworthy improvement in glycemic control (Figure 2).
case_images: Course of the patient's plasma insulin (microU/mL). SGLT2i, sodium-glucose cotransporter 2 inhibitor.   start of SGLT2i treatment.
case_images: fgene-15-1414451-g003.jpg
case_images: PMC11228259_01_fgene-15-1414451-g003.jpg
case_images: F3
case_images: However, plasma insulin levels remained elevated (Figure 3).